Status:
COMPLETED
Efficacy and Safety of Extract of Gelidium Elegans
Lead Sponsor:
Yonsei University
Conditions:
Obesity
Eligibility:
All Genders
19-50 years
Phase:
NA
Brief Summary
Extract of Gelidium elegans inhibits lipid differentiation, accumulation, and synthesis in vitro and in vivo. It has also anti-obesity effect by inhibiting weight gain and decreasing body fat. In a pr...
Eligibility Criteria
Inclusion
- 1\. Between the ages of 19 and 50
- 2\. BMI is at or greater than 23 and less than 30 kg/m\^2
Exclusion
- 1\. uncontrolled hypertension
- 2\. uncontrolled diabetes
- 3\. current serious cerebrovascular and cardiovascular disease
Key Trial Info
Start Date :
November 8 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 23 2018
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT03842774
Start Date
November 8 2017
End Date
November 23 2018
Last Update
February 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Family Medicine, Severance Hospital, College of Medicine, Yonsei University
Seoul, South Korea